Andrew Jonghan Woo

Andrew Jonghan Woo

Auto-generated profile, based on publicly available information

Andrew Jonghan Woo

Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Crawley, WA 6009, Australia

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Cell
Verified
Journal Article
Closed access
JKJonghwan Kim
Jonghwan Kim
AWAndrew J. Woo
Andrew J. Woo
JCJianlin Chu
Jianlin Chu
JSJonathan W. Snow
Jonathan W. Snow
YFYuko Fujiwara
Yuko Fujiwara
SOStuart H. Orkin
Stuart H. Orkin

1 February 2012 in Molecular Cell
Verified
Journal Article
Closed access
MYMing Yu
Ming Yu
TMTali Mazor
Tali Mazor
HHHui Huang
Hui Huang
HHHsuan-Ting Huang
Hsuan-Ting Huang
KKKatie L. Kathrein
Katie L. Kathrein
ACAlan B. Cantor
Alan B. Cantor

1 August 2020 in Cancer Cell
Verified
Journal Article
Closed access
BSBasit Salik
Basit Salik
HYHangyu Yi
Hangyu Yi
NHNunki Hassan
Nunki Hassan
NSNancy Santiappillai
Nancy Santiappillai
BVBinje Vick
Binje Vick
JWJenny Y Wang
Jenny Y Wang

1 August 2009 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
HHHui Huang
Hui Huang
MYMing Yu
Ming Yu
TAThomas E. Akie
Thomas E. Akie
TMTyler B. Moran
Tyler B. Moran
AWAndrew J. Woo
Andrew J. Woo
ACAlan B. Cantor
Alan B. Cantor
The transcription factor RUNX-1 plays a key role in megakaryocyte differentiation and is mutated in cases of myelodysplastic syndrome and leukemia. In this study, we purified RUNX-1-containing multiprotein complexes from phorbol ester-induced L8057 murine megakaryoblastic cells and identified the ets transcription factor FLI-1 as a novel in vivo-associated factor. The interaction occurs via direct protein-protein interactions and results in synergistic transcriptional activation of the c-mpl promoter. Interestingly, the interaction fails to occur in uninduced cells. Gel filtration chromatography confirms the differentiation-dependent binding and shows that it correlates with the assembly of a complex also containing the key megakaryocyte transcription factors GATA-1 and Friend of GATA-1 (FOG-1). Phosphorylation analysis of FLI-1 with uninduced versus induced L8057 cells suggests the loss of phosphorylation at serine 10 in the induced state. Substitution of Ser10 with the phosphorylation mimic aspartic acid selectively impairs RUNX-1 binding, abrogates transcriptional synergy with RUNX-1, and dominantly inhibits primary fetal liver megakaryocyte differentiation in vitro. Conversely, substitution with alanine, which blocks phosphorylation, augments differentiation of primary megakaryocytes. We propose that dephosphorylation of FLI-1 is a key event in the transcriptional regulation of megakaryocyte maturation. These findings have implications for other cell types where interactions between runx and ets family proteins occur.

1 January 2014 in Molecular Cell
Verified
Journal Article
Closed access
PDPartha Pratim Das
Partha Pratim Das
ZSZhen Shao
Zhen Shao
SBSemir Beyaz
Semir Beyaz
EAEftychia Apostolou
Eftychia Apostolou
LPLuca Pinello
Luca Pinello
SOStuart H. Orkin
Stuart H. Orkin

3 August 2018 in Oncogene
Verified
Journal Article
Open access
PDF file
EWEdina Wang
Edina Wang
ASAnabel Sorolla
Anabel Sorolla
PCPaula T. Cunningham
Paula T. Cunningham
HBHeique M. Bogdawa
Heique M. Bogdawa
SBSamuel Beck
Samuel Beck
PBPilar Blancafort
Pilar Blancafort
Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a functional penetrating ‘Phylomer’ peptide (FPPa) as a therapeutic strategy to inhibit MYC in TNBC. We found FPPa-OmoMYC to be a potent inducer of apoptosis (with IC50 from 1–2 µM) in TNBC cells with negligible effects in non-tumorigenic cells. Transcriptome analysis of FPPa-OmoMYC-treated cells indicated that the fusion protein inhibited MYC-dependent networks, inducing dynamic changes in transcriptional, metabolic, and apoptotic processes. We demonstrated the efficacy of FPPa-OmoMYC in inhibiting breast cancer growth when injected orthotopically in TNBC allografts. Lastly, we identified strong pharmacological synergisms between FPPa-OmoMYC and chemotherapeutic agents. This study highlights a novel therapeutic approach to target highly aggressive and chemoresistant MYC-activated cancers.